{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:14:58Z","timestamp":1790738098560,"version":"4.1.0"},"reference-count":16,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"1","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,11]]},"abstract":"<jats:title>ABSTRACT.<\/jats:title>\n<jats:p>An open label, phase IIa study conducted in Ethiopia evaluated the efficacy, safety, tolerability, and pharmacokinetics of a single 120-mg dose of the phosphatidylinositol 4-kinase inhibitor MMV390048 in <jats:italic>Plasmodium vivax<\/jats:italic> malaria. The study was not completed for operational reasons and emerging teratotoxicity data. For the eight adult male patients enrolled, adequate clinical and parasitological response at day 14 (primary endpoint) was 100% (8\/8). Asexual parasites and gametocytes were cleared in all patients by 66 and 78 hours postdose, respectively. There were two recurrent <jats:italic>P. vivax<\/jats:italic> infections (days 20 and 28) and a new <jats:italic>Plasmodium falciparum<\/jats:italic> infection (day 22). MMV390048 exposure in <jats:italic>P. vivax<\/jats:italic> patients was lower than previously observed for healthy volunteers. Mild adverse events, mainly headache and gastrointestinal symptoms, were reported by eight patients. Single-dose MMV390048 (120 mg) rapidly cleared asexual parasites and gametocytes in patients with <jats:italic>P. vivax<\/jats:italic> malaria and was well tolerated.<\/jats:p>","DOI":"10.4269\/ajtmh.22-0567","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T15:02:46Z","timestamp":1670252566000},"page":"81-84","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy, Safety, Tolerability, and Pharmacokinetics of MMV390048 in Acute Uncomplicated Malaria"],"prefix":"10.4269","volume":"108","author":[{"given":"Rezika","family":"Mohammed","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Gondar Hospital, Gondar, Ethiopia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mezgebu Silamsaw","family":"Asres","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Gondar Hospital, Gondar, Ethiopia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esayas Kebede","family":"Gudina","sequence":"additional","affiliation":[{"name":"Jimma University Clinical Trial Unit, Jimma University Institute of Health, Jimma, Ethiopia;"},{"name":"Department of Internal Medicine, Jimma University Institute of Health, Jimma, Ethiopia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wondimagegn","family":"Adissu","sequence":"additional","affiliation":[{"name":"Jimma University Clinical Trial Unit, Jimma University Institute of Health, Jimma, Ethiopia;"},{"name":"School of Medical Laboratory Sciences, Jimma University Institute of Health, Jimma, Ethiopia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Johnstone","sequence":"additional","affiliation":[{"name":"HJ-Clinical Trial Consultancy, George, South Africa;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Claire","family":"Marrast","sequence":"additional","affiliation":[{"name":"Medicines for Malaria Venture, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Donini","sequence":"additional","affiliation":[{"name":"Medicines for Malaria Venture, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Duparc","sequence":"additional","affiliation":[{"name":"Medicines for Malaria Venture, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Yilma","sequence":"additional","affiliation":[{"name":"Jimma University Clinical Trial Unit, Jimma University Institute of Health, Jimma, Ethiopia;"},{"name":"Department of Internal Medicine, Jimma University Institute of Health, Jimma, Ethiopia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","year":"2021"},{"key":"b2","series-title":"Trends Parasitol","first-page":"709","article-title":"Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials","volume":"37","year":"2021"},{"key":"b3","series-title":"Molecules","first-page":"5949","article-title":"Plasmodial kinase inhibitors targeting malaria: recent developments","volume":"25","year":"2020"},{"key":"b4","series-title":"Biochemistry","first-page":"2494","article-title":"Heterologous expression, purification, and functional analysis of the Plasmodium falciparum phosphatidylinositol 4-kinase iiibeta","volume":"59","year":"2020"},{"key":"b5","series-title":"Malar J","first-page":"38","article-title":"Identification of Plasmodium PI4 kinase as target of MMV390048 by chemoproteomics","volume":"13","year":"2014"},{"key":"b6","series-title":"Sci Transl Med","first-page":"eaad9735","article-title":"Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase","volume":"9","year":"2017"},{"key":"b7","series-title":"Antimicrob Agents Chemother","first-page":"e01896-19","article-title":"Safety, tolerability, pharmacokinetics, and antimalarial activity of the novel Plasmodium phosphatidylinositol 4-kinase inhibitor MMV390048 in healthy volunteers","volume":"64","year":"2020"},{"key":"b8","series-title":"Clin Infect Dis","first-page":"e657","article-title":"A phase 1, placebo-controlled, randomized, single ascending dose study and a volunteer infection study to characterize the safety, pharmacokinetics, and antimalarial activity of the Plasmodium phosphatidylinositol 4-kinase inhibitor MMV390048","volume":"71","year":"2020"},{"key":"b9","year":"2017"},{"key":"b10","year":"2016"},{"key":"b11","series-title":"Malar J","first-page":"319","article-title":"Utility of ultra-sensitive qPCR to detect Plasmodium falciparum and Plasmodium vivax infections under different transmission intensities","volume":"19","year":"2020"},{"key":"b12","series-title":"Malar J","first-page":"234","article-title":"A non-lethal malarial infection results in reduced drug metabolizing enzyme expression and drug clearance in mice","volume":"18","year":"2019"},{"key":"b13","series-title":"Malar J","first-page":"81","article-title":"Up- and down-modulation of liver cytochrome P450 activities and associated events in two murine malaria models","volume":"9","year":"2010"},{"key":"b14","series-title":"Biochem Pharmacol","first-page":"1341","article-title":"Effects of malarial infection on host microsomal drug-metabolizing enzymes","volume":"19","year":"1970"},{"key":"b15","series-title":"Clin Pharmacokinet","first-page":"913","article-title":"Clinical significance of the cytochrome P450 2C19 genetic polymorphism","volume":"41","year":"2002"},{"key":"b16","series-title":"Pharmacol Rev","first-page":"369","article-title":"Pharmacogenetics in biological perspective","volume":"49","year":"1997"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/108\/1\/article-p81.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/108\/1\/article-p81.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/108\/1\/article-p81.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T06:08:56Z","timestamp":1675404536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/108\/1\/article-p81.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":16,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.22-0567","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]}}}